The Mexico Prefilled Syringes Market was valued at $70.9 Million in 2026 and projected to reach to $99.6 Million by 2031, representing a compound annual growth rate of 7.0%. Mexico's prefilled syringes market is positioned for sustained growth as healthcare providers and patients increasingly recognize the benefits of pre-filled injection systems for improved medication adherence and reduced administration errors.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico's prefilled syringes market is valued at USD 70.9 million in 2026 and is projected to reach USD 99.6 million by 2031, representing a steady 7.0% CAGR over the forecast period.
Increasing adoption of injectable biologics for chronic disease management is a primary driver of prefilled syringe demand across Mexico's healthcare system.
Significant investments in Mexico's healthcare infrastructure and pharmaceutical distribution networks are expanding access to advanced drug delivery systems in both urban and emerging markets.
Rising prevalence of chronic diseases including diabetes, rheumatoid arthritis, and autoimmune disorders is driving demand for convenient, self-administered injectable therapies in Mexico.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SAFETY PREFILLED SYRINGES (Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.9% from 2026 to 2031 |
| Largest Segment | CONVENTIONAL PREFILLED SYRINGES (Type) |
| Market Size Base Year (Billions) | ~USD 8.66 (2026) |
| Revenue Forecast (Billions) | ~USD 14.53 (2031) |
| Segments Covered | Type, Design, Material, Application |
4 segment dimensions are covered across the global market.
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ANAPHYLAXIS | 3.8 | 4.1 | 4.5 | 4.9 | 5.3 | 5.8 | 6.4 | 7 | 9.2 |
| CANCER | 18.9 | 20.9 | 23.1 | 25.6 | 28.3 | 31.4 | 34.8 | 38.6 | 10.8 |
| DIABETES | 18.5 | 19.8 | 21.2 | 22.6 | 24.2 | 26 | 27.8 | 29.8 | 7.1 |
| OPHTHALMOLOGY | 2.5 | 2.6 | 2.7 | 2.8 | 2.9 | 3 | 3.1 | 3.2 | 3.6 |
| OTHER APPLICATIONS | 7.2 | 7.8 | 8.5 | 9.2 | 10 | 10.9 | 11.9 | 12.9 | 8.8 |
| RHEUMATOID ARTHRITIS | 16.2 | 17.2 | 18.3 | 19.4 | 20.6 | 21.9 | 23.3 | 24.8 | 6.3 |
| THROMBOSIS | 6.1 | 6.5 | 6.8 | 7.2 | 7.5 | 7.9 | 8.3 | 8.8 | 5.2 |
| TOTAL | 73.2 | 78.9 | 85 | 91.7 | 99 | 107 | 115.6 | 125 | 8 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Conventional prefilled syringe automation,Safety prefilled syringe automation,Glass prefilled syringe–focused systems, |
| CONSORT MEDICAL | United Kingdom | Private Company | Conventional prefilled syringes,Safety prefilled syringes,Glass prefilled syringes, |
| HENRY SCHEIN | United States | Public Company | Conventional Prefilled Syringes,Safety Prefilled Syringes,Glass Prefilled Syringes, |
| FLUOR CORPORATION | United States | Public Company | Conventional Prefilled Syringe Infrastructure,Safety Prefilled Syringe Infrastructure,Glass Prefilled Syringe Facilities, |
| MERIT MEDICAL | United States | Public Company | Conventional Prefilled Syringes,Safety Prefilled Syringes,Glass Prefilled Syringes, |
| GUERBET GROUP | France | InvalidIdentifier | Conventional prefilled syringes,Safety prefilled syringes,Glass prefilled syringes, |
| BECTON, DICKINSON AND COMPANY (BD) | United States | ||
| GERRESHEIMER AG | Germany | Public Company | Conventional prefilled syringes,Safety prefilled syringes,Glass prefilled syringes, |
| SCHOTT | Germany | Public Company | Glass prefilled syringes (syriQ, syriQ BioPure, silicone-free),Polymer prefilled syringes (TOPPAC portfolio),Cartridges (cartriQ, dual-chamber, large volume), |
| WEST PHARMACEUTICAL SERVICES, INC. | United States | Public Company | Conventional prefilled syringes,Safety prefilled syringes,Glass prefilled syringe containment and components, |
| APTARGROUP, INC. | United States | Public Company | Conventional prefilled syringe components,Safety prefilled syringe and device-integrated systems,Glass prefilled syringe-related solutions, |
| NIPRO | Japan | Public Company | Glass Prefilled Syringe,Plastic Prefilled Syringe,Conventional Prefilled Syringe, |
| NOVARTIS AG | Switzerland | Public Company | Conventional Prefilled Syringes,Safety Prefilled Syringes,Glass Prefilled Syringe, |
| STEVANATO GROUP | Italy | Public Company | Conventional prefilled syringes,Safety prefilled syringes,Glass prefilled syringes, |
| POLYMEDICURE | India | Public Company | Conventional Prefilled Syringes,Safety Prefilled Syringes,Glass Prefilled Syringes, |
| SHARPS TECHNOLOGY, INC. | United States | Public Company | Conventional Prefilled Syringes,Safety Prefilled Syringes,Glass Prefilled Syringes, |
ATS Automation Tooling Systems Inc is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.
Consort Medical is a United Kingdom-based private company established in 1938 with 2,000 employees. The company operates in the medical devices and pharmaceutical sectors.
Henry Schein is a United States public company founded in 1932 with 25,000 employees. The company is a distributor of healthcare products and services to dental, medical, and veterinary markets.
Fluor Corporation is a United States public company founded in 1912 with 22,995 employees. The company provides engineering, procurement, and construction services to the energy, chemicals, and infrastructure sectors.
Merit Medical is a United States public company founded in 1987 with 7,500 employees. The company designs, manufactures, and distributes medical devices for interventional medicine and vascular access.
Guerbet Group is a French company in the medical imaging and pharmaceutical sectors. Specific operational details are unavailable.
Becton, Dickinson and Company (BD) is a United States-based medical technology company. Specific founding date and employee count details are unavailable.
Gerresheimer AG is a German public company founded in 1864 with 13,528 employees. The company manufactures specialty glass and plastic products for the pharmaceutical and healthcare industries.
Schott is a German public company founded in 1884 with 4,839 employees. The company produces specialty glass and glass-ceramic products for pharmaceutical, laboratory, and industrial applications.
West Pharmaceutical Services, Inc. is a United States public company founded in 1923 with 10,800 employees. The company manufactures packaging and delivery systems for injectable drugs and healthcare products.
AptarGroup, Inc. is a United States public company founded in 1992 with 14,000 employees. The company designs and manufactures dispensing systems and closures for the pharmaceutical, beauty, and food industries.
Nipro is a Japanese public company founded in 1947 with 38,593 employees. The company manufactures and distributes medical devices, pharmaceuticals, and healthcare products globally.
Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a global pharmaceutical and healthcare company developing innovative medicines and treatments.
Stevanato Group is an Italian public company founded in 1949 with 6,010 employees. The company manufactures glass and plastic packaging solutions for the pharmaceutical industry.
Polymedicure is an Indian public company founded in 1995 with 3,082 employees. The company manufactures and distributes medical devices and healthcare products.
Sharps Technology, Inc. is a United States public company founded in 2017. Specific employee count details are unavailable.
Mexico's prefilled syringes market is estimated at USD 70.9 million in 2026 and is expected to grow to USD 99.6 million by 2031.
Mexico's prefilled syringes market is projected to grow at a compound annual growth rate (CAGR) of 7.0% from 2026 to 2031.
Key drivers in Mexico include rising chronic disease prevalence, increased adoption of injectable biologics, healthcare infrastructure modernization, and growing demand for safer drug delivery mechanisms.
Mexico's prefilled syringe demand is strongest in autoimmune disease treatment, oncology, and biologics administration, where injectable therapies are increasingly prevalent.
Mexico represents a significant portion of Latin America's prefilled syringes market, driven by its large population, advanced healthcare infrastructure, and role as a regional pharmaceutical hub.
This study involved four major activities in estimating the current prefilled syringes market size. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the prefilled syringes market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the prefilled syringes market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents for the prefilled syringes market is provided below:

**Others include sales, marketing, and product managers.
Note 1: C-level executives include CEOs, COOs, and CTOs.
Note 2: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3 = <USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
The research methodology used to estimate the size of the prefilled syringes market includes the following details.
The market sizing of the market was undertaken from the global side.
Country-level Analysis: The size of the prefilled syringes market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products and services in the overall prefilled syringes market was obtained from secondary data and validated by primary participants to arrive at the total prefilled syringes market. Primary participants further validated the numbers.
Geographic Market Assessment (By Region & Country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by prefilled syringes and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall prefilled syringes market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Prefilled syringes are a convenient way to deliver parenteral medications or a single-dose packet of medication with a premeasured dose. This method of drug administration offers advantages for manufacturers in terms of reducing drug waste and extending product lifespan. Additionally, it provides ease of self-administration for patients at home and in non-hospital settings. Some examples of drugs packaged in prefilled syringes include biologics, vaccines, blood stimulants, therapeutic proteins, erythropoietin products, and interferons.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Prefilled Syringes Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report